// App-Quantinova.ai

838TiP : ARASENS: A phase 3 trial of darolutamide in males with metastatic hormone-sensitive prostate cancer (mHSPC)

Researchers

Presenter

  • B.Tombal

Principal Investigators

  • F.Saad

  • M.Hussain

  • C.N.Sternberg

  • K.Fizazi

  • E.D.Crawford

  • K.Yamada

  • C.Kappeler

  • I.Kuss

  • M.R.Smith

Medical Centers

  • Urology, Cancer Centre, Catholic University of Louvain (UCL), Brussels, Belgium

  • Department of Surgery, University of Montreal Hospital Center/CRCHUM, University of Montreal, QC, Canada

  • Divsion of Hematology and Medical Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL

  • Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy

  • Cancer Medicine, Gustave Roussy, University of Paris Sud, Villejuif, France

  • Urologic Oncology, University of Colorado, School of Medicine, Aurora, CO, USA

  • Oncology, Bayer Healthcare Pharmaceuticals Inc., Whippany, NJ, USA

  • Clinical Statistics, Bayer AG, Berlin, Germany

  • CD Oncology AR Inhib, Bayer AG, Berlin, Germany

  • Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA

Locations

  • Belgium

  • Canada

  • United States

  • Italy

  • France

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Alkaline phosphatase

  • Dihydrotestosterone

  • Docetaxel

  • Androgen Tear

  • ODM201

  • Epimorph

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Multinational

  • Controlled

Phase

  • III

Study Id's

  • N/A

Sponsors

  • Bayer

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved